Baekkeskov S, Aanstoot H J, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P
Department of Microbiology, University of California San Francisco School of Medicine 94143.
Nature. 1990 Sep 13;347(6289):151-6. doi: 10.1038/347151a0.
The pancreatic islet beta-cell autoantigen of relative molecular mass 64,000 (64K), which is a major target of autoantibodies associated with the development of insulin-dependent diabetes mellitus (IDDM) has been identified as glutamic acid decarboxylase, the biosynthesizing enzyme of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid). Pancreatic beta cells and a subpopulation of central nervous system neurons express high levels of this enzyme. Autoantibodies against glutamic acid decarboxylase with a higher titre and increased epitope recognition compared with those usually associated with IDDM are found in stiff-man syndrome, a rare neurological disorder characterized by a high coincidence with IDDM.
相对分子质量为64,000(64K)的胰岛β细胞自身抗原,是与胰岛素依赖型糖尿病(IDDM)发病相关的自身抗体的主要靶标,已被鉴定为谷氨酸脱羧酶,即抑制性神经递质γ-氨基丁酸(GABA)的生物合成酶。胰腺β细胞和中枢神经系统神经元的一个亚群表达这种酶的高水平。在僵人综合征中发现了针对谷氨酸脱羧酶的自身抗体,其滴度较高且表位识别增加,与通常与IDDM相关的自身抗体相比,僵人综合征是一种罕见的神经系统疾病,其特征是与IDDM高度并发。